@article{e592dff2ad8e471caaae39739a02d9fb,
title = "Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline",
abstract = "Ventricular volume (VV) is a widely used structural magnetic resonance imaging (MRI) biomarker in Alzheimer's disease (AD) research. Abnormal enlargements of VV can be detected before clinically significant memory decline. However, VV does not pinpoint the details of subregional ventricular expansions. Here we introduce a ventricular morphometry analysis system (VMAS) that generates a whole connected 3D ventricular shape model and encodes a great deal of ventricular surface deformation information that is inaccessible by VV. VMAS contains an automated segmentation approach and surface-based multivariate morphometry statistics. We applied VMAS to two independent datasets of cognitively unimpaired (CU) groups. To our knowledge, it is the first work to detect ventricular abnormalities that distinguish normal aging subjects from those who imminently progress to clinically significant memory decline. Significant bilateral ventricular morphometric differences were first shown in 38 members of the Arizona APOE cohort, which included 18 CU participants subsequently progressing to the clinically significant memory decline within 2 years after baseline visits (progressors), and 20 matched CU participants with at least 4 years of post-baseline cognitive stability (non-progressors). VMAS also detected significant differences in bilateral ventricular morphometry in 44 Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects (18 CU progressors vs. 26 CU non-progressors) with the same inclusion criterion. Experimental results demonstrated that the ventricular anterior horn regions were affected bilaterally in CU progressors, and more so on the left. VMAS may track disease progression at subregional levels and measure the effects of pharmacological intervention at a preclinical stage.",
keywords = "Alzheimer's disease, Cognitively unimpaired subjects, Memory decline, Multivariate tensor-based morphometry, Ventricular abnormalities, Ventricular surface",
author = "Qunxi Dong and Wen Zhang and Stonnington, {Cynthia M.} and Jianfeng Wu and Gutman, {Boris A.} and Kewei Chen and Yi Su and Baxter, {Leslie C.} and Thompson, {Paul M.} and Reiman, {Eric M.} and Caselli, {Richard J.} and Yalin Wang",
note = "Funding Information: Algorithm development and image analysis for this study was funded, in part, by the National Institute on Aging (R21AG043760 to RJC and YW; RF1AG051710 to QD, WZ, JW, PMT, and YW; R01AG031581 and P30AG19610 to EMR and RJC); the National Institute of Biomedical Imaging and Bioengineering (R01EB025032 to WZ, JW, and YW; U54EB020403 to BAG, PMT, WZ, JW, and YW); and the Arizona Alzheimer's Consortium (CMS, WZ, JW, YS, KC, LCB, EMR, RJC, and YW). Part of data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904), and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co. Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: Part of data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904), and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer{\textquoteright}s Association; Alzheimer{\textquoteright}s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer{\textquoteright}s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: Algorithm development and image analysis for this study was funded, in part, by the National Institute on Aging (R21AG043760 to RJC and YW; RF1AG051710 to QD, WZ, JW, PMT, and YW; R01AG031581 and P30AG19610 to EMR and RJC); the National Institute of Biomedical Imaging and Bioengineering (R01EB025032 to WZ, JW, and YW; U54EB020403 to BAG, PMT, WZ, JW, and YW); and the Arizona Alzheimer's Consortium (CMS, WZ, JW, YS, KC, LCB, EMR, RJC, and YW). Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2020",
doi = "10.1016/j.nicl.2020.102338",
language = "English (US)",
volume = "27",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "Elsevier BV",
}